Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial
- PMID: 17152015
- PMCID: PMC2871300
- DOI: 10.1086/509896
Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial
Abstract
Background: Most new tuberculosis vaccines will be administered as a booster to subjects primed with bacille Calmette-Guérin (BCG) during childhood.
Methods: We investigated in vivo and in vitro immune responses to mycobacteria in human immunodeficiency virus (HIV)-positive subjects in Tanzania primed with BCG during childhood and entering a tuberculosis booster vaccine trial. Tests included intradermal skin testing for Mycobacterium tuberculosis purified protein derivative (PPD) and Mycobacterium avium sensitin (MAS); lymphocyte proliferation assays and interferon (IFN)-gamma levels after stimulation with Mycobacterium vaccae sonicate (MVS), M. tuberculosis early secreted antigen (ESAT)-6, M. tuberculosis antigen 85 (Ag85), or M. tuberculosis whole-cell lysate (WCL); and determination of serum antibody to lipoarabinomannin (LAM).
Results: A total of 888 subjects with CD4 cell counts > or = 200 cells/mm3 were enrolled. PPD and MAS test results were positive in 34% and 30% of the subjects, respectively. Proliferative responses were detected as follows: MVS, 6%; Ag85, 24%; ESAT-6, 21%; and WCL, 59%. IFN-gamma responses were 2%, 6%, 12%, and 38%, respectively. LAM antibody was detected in 28% of the subjects. Subjects were more likely to have detectable proliferative and IFN-gamma responses if they had positive PPD test results or CD4 cell counts > or = 500 cells/mm3. Overall, 94% of the subjects had evidence of primed mycobacterial immune responses.
Conclusion: Of HIV-positive BCG-immunized adults with CD4 cell counts > or = 200 cells/mm3 in Tanzania, 94% are primed for booster mycobacterial immunization.
Conflict of interest statement
Potential conflicts of interest: none reported.
Figures

Similar articles
-
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.J Infect Dis. 2010 Oct 15;202(8):1265-72. doi: 10.1086/656332. J Infect Dis. 2010. PMID: 20812851 Free PMC article. Clinical Trial.
-
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.BMC Infect Dis. 2009 Feb 23;9:21. doi: 10.1186/1471-2334-9-21. BMC Infect Dis. 2009. PMID: 19236695 Free PMC article. Clinical Trial.
-
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.AIDS. 2003 Nov 7;17(16):2351-5. doi: 10.1097/00002030-200311070-00010. AIDS. 2003. PMID: 14571187 Clinical Trial.
-
Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology.Clin Exp Immunol. 2012 Sep;169(3):213-9. doi: 10.1111/j.1365-2249.2012.04614.x. Clin Exp Immunol. 2012. PMID: 22861360 Free PMC article. Review.
-
Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.Vaccine. 2014 Feb 3;32(6):712-6. doi: 10.1016/j.vaccine.2013.11.065. Epub 2013 Dec 2. Vaccine. 2014. PMID: 24300592 Review.
Cited by
-
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.AIDS. 2010 Mar 13;24(5):675-85. doi: 10.1097/QAD.0b013e3283350f1b. AIDS. 2010. PMID: 20118767 Free PMC article. Clinical Trial.
-
Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.J Infect Dis. 2010 Oct 15;202(8):1265-72. doi: 10.1086/656332. J Infect Dis. 2010. PMID: 20812851 Free PMC article. Clinical Trial.
-
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.BMC Infect Dis. 2009 Feb 23;9:21. doi: 10.1186/1471-2334-9-21. BMC Infect Dis. 2009. PMID: 19236695 Free PMC article. Clinical Trial.
-
Microphysiologic Human Tissue Constructs Reproduce Autologous Age-Specific BCG and HBV Primary Immunization in vitro.Front Immunol. 2018 Nov 20;9:2634. doi: 10.3389/fimmu.2018.02634. eCollection 2018. Front Immunol. 2018. PMID: 30524426 Free PMC article.
-
T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections.Clin Dev Immunol. 2011;2011:640309. doi: 10.1155/2011/640309. Epub 2010 Sep 27. Clin Dev Immunol. 2011. PMID: 20936150 Free PMC article.
References
-
- McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003;9:729–735. - PubMed
-
- Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 2005;26:660–667. - PubMed
-
- McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 2005;7:962–967. - PubMed
-
- Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol. 2003;171:1602–1609. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials